Anti-IL-1 Therapy in Management of Patients with Behçet’s Disease During the COVID-19 Pandemic

References (13)

1. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020; 19(5): 102523
2. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34(2): 327–31
3. Cron RQ, Chatham WW. The rheumatologist’s role in COVID-19. J Rheumatol 2020; 47(5): 639–42
4. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A 2020; 117(32): 18951–3
5. Pillaiyar T, Laufer S. Kinases as potential therapeutic targets for anti-coronaviral therapy. J Med Chem. 2021 Jun 3:acs.jmedchem.1c00335. doi: 10.1021/acs.jmedchem.1c00335. [Epub ahead of print]
6. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 2020; 40(6): 511–8
7. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384(8): 693–704
8. NCT04324021. Efficacy and safety of Emapalumab and Anakinra in reducing hyperinflammation and respiratory distress in patients with COVID-19 infection. Available from: URL: https://www.clinicaltrials. gov/ct2/show/NCT04324021
9. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2019: Behçet’s syndrome. Clin Exp Rheumatol 2019; 37 Suppl 121(6): 3–17
10. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018; 77(6): 808–18
11. Bettiol A, Silvestri E, Di Scala G, Amedei A, Becatti M, Fiorillo C, et al. The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review. Rheumatol Int 2019; 39(6): 971–90
12. International Society for Behçet’s Disease. BD and COVID-19 - management advice for clinicians. Available from: URL: https://www. behcetdiseasesociety.org/menu/56/bd-and-covid-19-managementadvice-for-clinicians. Accessed Sep 4, 2021
13. Behçet’s Disease Centres of Excellence. Behçet’s centres position statement on COVID-19 vaccine. Available from: URL: https://www. behcets.nhs.uk/behcets-centres-p